Sign in Subscribe
Edema

Research on Age-Related Macular Degeneration Examines Reimbursement Criteria Impact

Strategic Insights

— 1 min read

A recent study has shed new light on the relationship between reimbursement criteria and treatment patterns among patients with age-related macular degeneration (AMD) and diabetic macular edema (DME). Conducted using Taiwan's National Health Insurance (NHI) database, the research found that changes in reimbursement criteria significantly impacted treatment gaps between injections of anti-vascular endothelial growth factor (anti-VEGF) agents. The study's findings have important implications for understanding the impact of reimbursement policies on patient outcomes and visual health.

Key Takeaways:

  • The research analyzed data from 2011 to 2019 and identified patients with AMD or DME who received anti-VEGF injections.
  • Changes in reimbursement criteria led to significant reductions in treatment gaps between injections, with the cancellation of the annual three-needles limitation associated with the greatest decrease in treatment gaps.
  • The study found that treatment gaps between the third and fourth needles decreased by 228 days (95% CI -282, -173) in AMD patients, and by 110 days (95% CI -141, -79) in DME patients.
  • The study suggests that the shortened treatment gaps may be associated with better visual outcomes, but further research is needed to confirm this relationship.
  • The research demonstrates the importance of considering the impact of reimbursement policies on treatment patterns and patient outcomes in the management of AMD and DME.
  • The findings of this study have implications for policymakers, healthcare providers, and patients seeking to optimize treatment outcomes for AMD and DME.

Statistics:

  • 2011-2019: study period for data analysis.
  • 2014 (August): first intervention date for changes in reimbursement criteria for AMD patients.
  • 2016 (December): second intervention date for changes in reimbursement criteria for AMD patients.
  • 2016 (three consecutive): intervention data for changes in reimbursement criteria for DME patients.
  • -228 days (95% CI -282, -173): change in treatment gap between the third and fourth needles for AMD patients.
  • -110 days (95% CI -141, -79): change in treatment gap between the third and fourth needles for DME patients.
  • 209: issue number of Health & Medicine Week in which the study was reported.

Sources:

  • Changing Reimbursement Criteria on Anti-VEGF Treatment Patterns Among Wet Age-Related Macular Degeneration and Diabetic Macular Edema Patients: An Interrupted Time Series Analysis. International Journal of Health Policy and Management, 2024.
  • International Journal of Health Policy and Management: https://www.ijhpm.com/
  • Maad Rayan Publishing Company: publisher of International Journal of Health Policy and Management.

Read more